Recipharm AB: Recipharm appoints Chief Strategy Officer

STOCKHOLM--()--Regulatory News:

Recipharm, (STO: RECI) the leading contract development and manufacturing organisation, is pleased to announce that it has appointed Jean-François Hilaire to the new position of Chief Strategy Officer to join Recipharm’s Group Management Team with effect from today.

Jean-François Hilaire is a pharmacist and graduated from the university of Bordeaux and alumni of the CEDEP General Manager Program (campus INSEAD – Fontainebleau). He brings a broad experience base acquired in Commercial as well as in Manufacturing & Supply leadership roles at Fournier, Solvay and Abbott.

Commenting on the appointment, Thomas Eldered CEO said “Jean- François Hilaire will bring valuable and relevant experience from the pharmaceutical industry in general but also very important views from outsourcing of pharmaceutical development and manufacturing”.

Jean-François said “I am glad to be joining Recipharm and its leadership team whom I have had the chance to know for several years and admire their entrepreneurship. Furthermore, with the current transformation of the pharmaceutical industry, I see Recipharm as very well positioned to catch sizable business opportunities in extending the value created for its customers“.

This information is published in accordance with the Swedish Securities Market Act, the Swedish Financial Instruments Trading Act and/or the regulations of NASDAQ Stockholm. This information was submitted for publication on 1 June 2015, at 10:00 am CET.

About Recipharm Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 2,200 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. Recipharm manufactures more than 400 different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 3.3 billion and the Company operates development and manufacturing facilities in Sweden, France, the UK, Germany, Spain, Italy and Portugal and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on NASDAQ Stockholm.

For more information on Recipharm and our services, please visit www.recipharm.com

This information was brought to you by Cision http://news.cision.com

Contacts

Recipharm
Thomas Eldered, CEO
thomas.eldered@recipharm.com
+ 46 8 602 52 10
or
Jean-François Hilaire, CSO
jean-francois.hilaire@recipharm.com
+33 695 44 750
or
De Facto Communications
Tristan Jervis
t.jervis@defacto.com
or
Alex Heeley
a.heeley@defacto.com
Tel: +44 (0) 207 861 3019/3043

Contacts

Recipharm
Thomas Eldered, CEO
thomas.eldered@recipharm.com
+ 46 8 602 52 10
or
Jean-François Hilaire, CSO
jean-francois.hilaire@recipharm.com
+33 695 44 750
or
De Facto Communications
Tristan Jervis
t.jervis@defacto.com
or
Alex Heeley
a.heeley@defacto.com
Tel: +44 (0) 207 861 3019/3043